Treatment of cytomegalovirus diseases.
Treatment of cytomegalovirus diseases.
复制标题
治疗巨细胞病毒疾病。
DOI：
10.1159/000150568
复制
发表时间：
1997
期刊：
影响因子：
4.6
通讯作者：
J. Činátl
中科院分区：
文献类型：
--
作者：
J. Vogel;M. Scholz;J. Činátl
本文综述了目前的策略，用于治疗人类巨细胞病毒（CMV）感染/疾病的高危患者，如移植受者和艾滋病患者。由于主要药物更昔洛韦（Cytovene），膦甲酸（Foscavir）和西多福韦（Vistide）经常与严重的副作用和病毒耐药性的形成相关，因此应开发更好的抗CMV治疗策略。此外，阻断病毒复制并不总是解决通常与CMV相关的免疫病理机制相关的表现。因此，也讨论了现有药物的疗效，根据其调节细胞介导的免疫系统的炎症组分的能力。
This review summarizes current strategies for the treatment of human cytomegalovirus (CMV) infection/diseases in high-risk patients such as transplant recipients and AIDS patients. Since the major drugs ganciclovir (Cytovene), foscarnet (Foscavir) and cidofovir (Vistide) are frequently associated with severe side effects and the formation of viral resistance, it should be endeavored to develop better strategies in anti-CMV treatment. Moreover, blocking of the viral replication does not always resolve the manifestations which are often linked with CMV-associated immunopathomechanisms. Thus, the efficacy of the available drugs is also discussed in the light of their ability to modulate inflammatory components of the cell-mediated immune system.